12th Feb 2014 15:29
LONDON (Alliance News) - Vectura Group PLC Wednesday said its partner has received Belgian marketing authorisation for its new inhaler for people with asthma, triggering a payment to Vectura of EUR1.5 million.
In a statement, Vectura said partner Sandoz has received approval for the AirFluSal Forspiro inhaler for patients with asthma and chronic obstructive pulmonary disease.
Receipt of the approval triggered the payment.
The product has already received approval in Denmark, Germany, and Sweden, among several other countries.
Vectura shares were Wednesday quoted at 155.938 pence, up 0.688 pence, or 0.4%.
By Samuel Agini; [email protected]; @samuelagini
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L